Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation

Fetal Diagnosis and Therapy

Volumn 30, Issue 4, 2011, Pages 274-279

  Bredaki, Foteini E ^a   Wright, David ^c   Akolekar, Ranjit ^a   Cruz, Grasielle ^a   Nicolaides, Kypros H ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Alpha Fetoprotein; First trimester screening; Free hCG; PAPP A; Pyramid of prenatal care

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BIRTH WEIGHT; CONCENTRATION (PARAMETERS); CONCEPTION; ETHNICITY; FEMALE; FERTILIZATION IN VITRO; GESTATIONAL AGE; HUMAN; INFORMATION RETRIEVAL; LIVE BIRTH; MATERNAL AGE; MATERNAL SERUM; MATERNAL SMOKING; MATERNAL WEIGHT; NORMAL HUMAN; OVULATION INDUCTION; PRENATAL SCREENING; PRIORITY JOURNAL; WEIGHT;

ALPHA-FETOPROTEINS; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; REGRESSION ANALYSIS; SERUM;

EID: 82955187099     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000330200     Document Type: Article

References (42)

1. 274-279 1 Merkatz IR, Nitowsky HM, Macri JN, Johnson WE: An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886-894. (Pubitemid 14125705)
2. Cuckle HS: Biochemical screening for Down syndrome. Eur J Obstet Gynecol Rep Biol 2000; 92: 97-101.
3. Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP: Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural- tube defects. Lancet 1977; 1: 1323-1332. (Pubitemid 8127680)
4. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; FASTER Trial Research Consortium: Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005; 106: 260-267. (Pubitemid 41023261)
5. Huang T, Hoffman B, Meschino W, Kingdom J, Okun N: Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn 2010; 30: 471-477.
6. Nicolaides KH, Campbell S, Gabbe SG, Guidetti R: Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986; 2: 72-74. (Pubitemid 16097081)
7. Ghi T, Pilu G, Falco P, Segata M, Carletti A, Cocchi G, Sanini D, Bonasoni P, Tani G, Rizzo N: Prenatal diagnosis of open and closed spina bifida. Ultrasound Obstet Gynecol 2006; 28: 899-903. (Pubitemid 46025207)
8. Snijders RMJ, Noble P, Sebire N, Souka A, Nicolaides KH: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998; 351: 343-346. (Pubitemid 28352196)
9. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
10. Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH: Maternal serum -fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery. Fetal Diagn Ther 2011; 30: 88-93.
11. Cuckle HS, van Lith JMM: Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-512. (Pubitemid 29271812)
12. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH: First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
13. Robinson HP, Fleming JE: A critical evaluation of sonar 'crown-rump length' measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
14. Draper NR, Smith H: Applied Regression Analysis, ed 2. John Wiley and Sons Ltd., USA, 1981.
15. Macri JN, Weiss RR, Elligers KW, Federgreen WR: Racial differences in maternal serum-alpha-fetoprotein. Lancet 1976; 1: 207-208.
16. Crandall BF, Lebherz TB, Schroth PC, Matsumoto M: Alpha-fetoprotein concentrations in maternal serum: relation to race and body weight. Clin Chem 1983; 29: 531-533. (Pubitemid 13160768)
17. Baumgarten A: Racial difference and biological significance of maternal serum alphafetoprotein. Lancet 1986; 2: 573. (Pubitemid 16054654)
18. Benn PA, Clive JM, Collins R: Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Clin Chem 1997; 43: 333-337. (Pubitemid 27066500)
19. O'Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. Obstet Gynecol 1997; 89: 355-358. (Pubitemid 27086087)
20. Thomsen SG, Isager-Sally L, Lange AP, Saurbrey N, Schiølier V. Smoking habits and maternal serum alpha-fetoprotein levels during the second trimester of pregnancy. Br J Obstet Gynaecol 1983; 90: 716-717. (Pubitemid 13031751)
21. Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, Palomaki GE: The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 1990; 97: 272-274. (Pubitemid 20158015)
22. Bartels I, Hoppe-Sievert B, Bockel B, Herold S, Caesar J: Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol to maternal weight and smoking. Prenat Diagn 1993; 13: 123-130. (Pubitemid 23083346)
23. Spencer K: The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 1998; 18: 225-234. (Pubitemid 28121141)
24. Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A: Influence of smoking habits on Down's syndrome risk evaluation at mid-trimester through biochemical screening. Int J Clin Lab Res 1998; 28: 179-182.
25. Hafner E, Stangl G, Rosen A, Schuchter K, Plattner M, Philipp K: Influence of cigarettesmoking on the result of the triple test. Gynecol Obstet Invest 1999; 47: 188-190. (Pubitemid 29145722)
26. Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor JM: Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn 2002; 22: 247-255. (Pubitemid 34245843)
27. Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK: Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn 2002; 22: 893-897. (Pubitemid 35175989)
28. Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H: Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996; 16: 1111-1114. (Pubitemid 27007631)
29. Ribbert LS, Kornman LH, De Wolf BT, Simons AH, Jansen CA, Beekhuis JR, Mantingh A: Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 1996; 16: 35-38. (Pubitemid 26031043)
30. Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN Jr: Serum triplemarker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 1997; 90: 98-101. (Pubitemid 27272965)
31. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA: Serum markers for Down's syndrome in women who have had in vitro ertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999; 106: 1304-1306.
32. Lam YH, Yeung WS, Tang MH, Ng EH, So WW, Ho PC: Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. Hum Reprod 1999; 14: 2120-2123. (Pubitemid 29381256)
33. Bar-Hava I, Yitzhak M, Krissi H, Shohat M, Shalev J, Czitron B, Ben-Rafael Z, Orvieto R: Triple-test screening in in vitro fertilization pregnancies. J Assist Reprod Genet 2001; 18: 226-229. (Pubitemid 32574603)
34. Maymon R, Shulman A: Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod 2001; 16: 691-695. (Pubitemid 32293797)
35. Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M, Martikainen H: Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 2002; 17: 794-797. (Pubitemid 34232454)
36. Maymon R, Shulman A: Serial first- and second- trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002; 17: 1081-1085. (Pubitemid 34411149)
37. Räty R, Virtanen A, Koskinen P, Anttila L, Forsström J, Laitinen P, Mörsky P, Tiitinen A, Ekblad U: Serum free beta-HCG and alpha- fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. Hum Reprod 2002; 17: 481-484.
38. Muller F, Dreux S, Lemeur A, Sault C, Desgrès J, Bernard MA, Giorgetti C, Lemay C, Mirallié S, Beauchet A; French Collaborative Group: Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. Prenat Diagn 2003; 23: 1073-1076. (Pubitemid 38084150)
39. Rice JD, McIntosh SF, Halstead AC: Secondtrimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. Prenat Diagn 2005; 25: 234-238. (Pubitemid 40478010)
40. Jauniaux, E, Burton, GJ: The effect of smoking in pregnancy on early placental morphology. Obstet Gynecol 1992; 79: 645-648.
41. Demir R, Demir AY, Yinanc M: Structural changes in placental barrier of smoking mother. Path Res Pract 1994; 190: 656-667.
42. Genabacev O, Bass KE, Joslin RJ, Fisher SJ: Maternal smoking inhibits early human cytotrophoblast differentiation. Reprod Toxicol 1995; 9: 245-255